GH secretagogue research
Ipamorelin.
7 vendors · €14–55
Synthetic pentapeptide described in 1998 by Novo Nordisk researchers as a selective ghrelin/GH-secretagogue receptor agonist; researched for growth-hormone release. Not approved for human therapeutic use.
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH₂
Compound specification
Formula
C₃₈H₄₉N₉O₅
CAS
170851-70-4
MW
711.9 g/mol
Half-life
2 hours (terminal half-life, human IV-infusion study; Gobburu et al. 1999)
Storage
Lyophilised powder below −15 °C in a tightly closed container, shielded from light; equilibrate the sealed vial to room temperature before opening. Reconstituted vials 2–8 °C.
Sizes
2 mg, 5 mg, 10 mg
Live vendor register · sorted by price
Every vendor. Same compound, sorted ascending.
IPAMORELIN · price-normalised
n = 7 vendors
01
Direct Peptides EU
VID-DIRECT-PHPLC badge only (no reports published)
99%
10–14 days · UK network · from £12.38
€14
03
QSC Peptides
VID-QSC-PEPTHPLC · MS · Janoshik
99%
5–7 days (domestic lane) · Kit of 10 · from $220
€19
06
PEAK_PEPTIDE
VID-PEAK-PEPLiquilabs per-batch COA
98.5%
Dispatch 24–48 h · AT dispatch · COA 98.5%
€27
07
PeptidesDirect
VID-PEPTIDESHPLC · MS (per-batch COA)
99.73%
DE 1–2 d · EU 3–10 d · DE dispatch
€55
Representative literature
Research context. Recent peer-reviewed work.
1998 · Eur. J. Endocrinol.
Ipamorelin, the first selective growth hormone secretagogue
1999 · Pharm. Res.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
2014 · Int. J. Colorectal Dis.
Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus
cited by n = 117
Long-form research guide
Weight Loss Research. Mechanism + protocols + safety.
Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models
Open the long-form guide for Ipamorelin →